OBJECTIVE:To study the hepatoprotective effect of the extract of Sabia parviflorawall(SPS) on mice with experimental liver injury.METHODS:The liver injury models were reproduced in mice with CCL4 and Paracetamol(AAP),respectively with the activities of serum ALT and AST measured.RESULTS:The activities of serum ALT and AST were all reduced to a certain degree in mice with liver injury induced by either CCL4 or Paracetamol(AAP).CONCLUSION: SPS exhibited certain hepatoprotective effect.

Objective To investigate potentially inappropriate medication(PIM)and influencing factors of elderly hospitalized patients,and to provide a reference for clinically rational drug use.Methods A total of 116 medical records of elderly hospitalized patients from October to December 2021 were collected.The Beers criteria(2019),Chinese PIM criteria(2017),and self-developed traditional Chinese medicine PIM criteria were applied respectively to analyze the potentially inappropriate medication situation.Analysis of influencing factors of PIM was also conducted.Results According to the Beers criteria(2019),42 items of PIM were discovered,and the drugs with high frequency were benzodiazepines.According to Chinese PIM criteria(2017),there were 49 items of PIM,mainly involving clopidogrel and nervous system drugs.According to self-developed traditional Chinese medicine PIM criteria,42 cases of PIM were screened,of which toxic conventional Chinese medicine and preparations containing harmful traditional Chinese medicine accounted for 40.5%.Influencing factors analysis showed the common influencing factors of PIM are department and the number of treatments used(P＜0.05).Conclusions Elderly inpatients have a high incidence of PIM.Due to the extensive use of traditional Chinese medicine and Chinese patent medicines by elderly patients,the exploratory construction of PIM standards for traditional Chinese medicine and screening for elderly inpatients'medical orders are necessary to ensure drug safety in elderly patients.

Objective To investigate the influencing factors for ribavirin (RBV)-induced hemolytic anemia in the treatment of chronic hepatitis C, and to provide a reference for the early prediction of ribavirin-related hemolytic anemia in clinical practice. Methods A total of 49 patients with chronic hepatitis C who attended or were hospitalized in Hebei Petrochina Central Hospital from January 2018 to July 2019 and received antiviral therapy with direct-acting antiviral agent (DAA) and RBV were enrolled, with a major allele of C allele and a minor allele of A allele at the rs1127354 locus of the inosine triphosphate pyrophosphatase (ITPA) gene, and the patients with AA and AC genotypes were compared with those with CC genotype. During treatment, RBV was reduced to 600 mg when hemoglobin (Hb) level was < 100 g/L and was withdrawn when Hb level was < 85 g/L. Routine blood test, liver function, liver stiffness measurement, HCV RNA, HCV genotype, and ITPA genotype were measured before antiviral therapy, and the routine blood test was performed at weeks 2, 4, 8, and 12 of treatment. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. Results A total of 49 patients were enrolled in this study, among whom 22 had chronic hepatitis C and 27 had liver cirrhosis, with a sustained virologic response (SVR) rate of 95.9%. The dose of RBV was reduced in 3 patients (2 in the AA/AC group and 1 in the CC group) due to anemia, and RBV was withdrawn in 3 patients (1 in the AA/AC group and 2 in the CC group); all these 6 patients had liver cirrhosis and finally achieved SVR. During the anti-HCV therapy with DAA+RBV, there was relatively mild RBV-related hemolysis, and the maximum reduction in Hb from baseline was compared between the patients with AA/AC genotype at ITPA rs1127354 and those with CC genotype, which showed no significant difference between the two groups ( Z =-0.18, P =0.87). Conclusion During the treatment with RBV+DAA, RBV is withdrawn or reduced for liver cirrhosis patients due to anemia, and no obvious statistical relation is observed between ITPA genotype and the maximum reduction in Hb from baseline. Therefore, detection of ITPA genotype before the application of RBV does not improve safety during treatment, and it is not recommended to perform conventional detection of ITPA gene polymorphisms.